Cellectis S.A. (CLLS) is a Paris-based clinical-stage gene-editing biotechnology company whose American depositary receipts trade on the Nasdaq. Following the company's September 2026 decision to discontinue its CAR-T programs lasme-cel and eti-cel and refocus on in vivo gene editing, three analysts issued current price targets: Barclays' Lukas Shumway downgraded the shares to Underweight with a $1.30 target; Wells Fargo's Nick Abbott kept an Equal Weight rating and cut his target to $3.00; and Robert W. Baird's Jack Allen lowered his target to $8.00. The arithmetic mean of these three valid targets is $4.10, within a wide $1.30-to-$8.00 range.
Older, pre-pivot targets — such as a $9.00 objective from Barclays and Clear Street and a $7.00 target from Jefferies — were treated as stale because they predate the company's fundamental repositioning. The dispersion among the three current targets reflects genuine disagreement: the bearish view argues the pivot leaves a preclinical, unproven story, while the bullish view sees optionality in Cellectis's TALEN-based in vivo platform. This is not a tightly clustered analyst consensus, and the mean should not be read as a guarantee.
With the ADR recently near $1.03, reaching $4.10 would require roughly a 298% gain — a very large move by any standard. The stock sits near the bottom of a 52-week range of approximately $0.88 to $5.45, having shed roughly 40% in a single session after the strategic announcement. The path toward the target would depend on early human data for the new pipeline: HEAL-101, a TALE base-editor targeting APOC3 for severe hypertriglyceridemia, and HEAL-201, targeting PCSK9 for severe hypercholesterolemia. Preliminary Phase 1 data are not expected until the second half of 2027 and first half of 2028, respectively, so the near-term story is primarily one of cash preservation, partnerships, and preclinical validation.
Several factors could underpin a recovery. Cellectis reported roughly $169 million in cash as of June 30, 2026, against a market capitalization near $100 million, leaving the shares trading near or below net cash value. The restructuring is expected to extend the cash runway into the second half of 2028. The company is retaining its cell-therapy collaborations with AstraZeneca, Allogene, Servier, and Iovance, which may generate milestone economics while the internal pipeline matures. In vivo gene editing for cardiometabolic disease is attracting substantial investor interest, and Cellectis's proprietary TALEN platform offers differentiation. Positive early biomarker or safety data in 2027 could materially reset the risk-reward calculus that currently anchors cautious targets.
The obstacles are substantial. The pivot abandons lasme-cel and eti-cel at a time when those programs had shown strong response rates and received regulatory designations, removing the nearest measurable catalysts. Clinical readouts are now more than a year away, and Barclays has questioned the preclinical data presented so far. The new indications are competitive: the APOC3 field already includes an approved therapy (plozasiran), and the PCSK9 space has established in vivo competitors. With negative earnings per share and no near-term profitability, the shares also face the technical risk of Nasdaq minimum-bid compliance concerns while trading near $1.00.
The shares' collapse reset the technical picture. The 52-week low near $0.88 stands as the key downside reference, while the $1.00 level carries both psychological and listing-compliance significance. On the upside, the stock must first reclaim the pre-pivot levels it surrendered in the low-to-mid $2.00 area before any credible move toward the higher analyst targets becomes visible; the prior 52-week high near $5.45 sits above even the highest current target.
Analyst price targets generally reflect a research horizon of roughly 12 months, though the specific horizons differ by firm, and Cellectis's own catalysts extend well beyond that window. Investors should watch for quarterly earnings updates and any commentary on cash runway and partnership milestones, plus preclinical or non-human-primate data that analysts such as Wells Fargo have flagged as de-risking events. Regulatory and trial-initiation announcements for HEAL-101 and HEAL-201 in China, and any signs of Nasdaq minimum-bid compliance actions, are also directly relevant to the target debate.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening. Because biotech names like Cellectis can move rapidly on pipeline news, tools that track technical and momentum shifts in real time may help traders stay oriented as the story evolves.
The $4.10 central target — the mean of three verified post-pivot analyst objectives spanning $1.30 to $8.00 — implies a roughly 298% move from recent levels near $1.03, a very large requirement that underscores how dramatically Cellectis's risk profile changed in September 2026. Support comes from a strong cash position, an extended runway, retained partnerships, and a differentiated in vivo platform. Against that stand the loss of late-stage assets, delayed catalysts, a crowded competitive field, and extreme analyst disagreement. Whether the shares can approach $4.10 will hinge on early clinical data in 2027 and 2028, execution on the new strategy, and the company's ability to preserve value in the interim — outcomes that remain genuinely uncertain and are not a prediction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CLLS has been loosely correlated with SLN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLLS jumps, then SLN could also see price increases.
| Ticker / NAME | Correlation To CLLS | 1D Price Change % | ||
|---|---|---|---|---|
| CLLS | 100% | +3.88% | ||
| SLN - CLLS | 43% Loosely correlated | +0.05% | ||
| MDGL - CLLS | 40% Loosely correlated | -0.12% | ||
| PMVP - CLLS | 38% Loosely correlated | -1.18% | ||
| AXON - CLLS | 36% Loosely correlated | -18.18% | ||
| TGTX - CLLS | 36% Loosely correlated | +3.18% | ||
More | ||||